Takeda Pharmaceutical (NYSE:TAK) Stock Rating Upgraded by Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Other analysts also recently issued research reports about the company. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 1.0%

TAK opened at $16.72 on Tuesday. Takeda Pharmaceutical has a twelve month low of $12.99 and a twelve month high of $18.90. The company’s 50-day moving average price is $16.30 and its two-hundred day moving average price is $17.09. The stock has a market cap of $53.57 billion, a price-to-earnings ratio of 49.17 and a beta of -0.08. The company has a quick ratio of 0.60, a current ratio of 1.14 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, equities analysts expect that Takeda Pharmaceutical will post 3.01 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of large investors have recently made changes to their positions in the business. Private Trust Co. NA increased its stake in shares of Takeda Pharmaceutical by 84.7% during the fourth quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares during the period. Parkside Financial Bank & Trust raised its holdings in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares in the last quarter. SHP Wealth Management purchased a new stake in Takeda Pharmaceutical in the fourth quarter worth $42,000. Caitong International Asset Management Co. Ltd lifted its stake in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after acquiring an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. boosted its holdings in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.